Obstetrics and Gynecology Drugs Market Size, Share | Industry Forecast by 2030 (2025)

Obstetrics and Gynecology Drugs Market Size

The obstetrics and gynecology drugs market size was USD 13,089.39 Million in 2021 and is expected to register a revenue CAGR of 7.5% during the forecast period. Market revenue growth is primarily driven by factors such as increase in awareness and use of contraceptives and Hormone Replacement Therapy (HRT), age-related increase in gynecological and ovarian cancer, prevalence of gynecological diseases, rise in healthcare expenditure, and rising investments to understand mechanisms of endometriosis and its treatment Obstetrics and gynecology drugs are used for treatment of various medical conditions, such as gynecological cancers, contraception, postmenopausal disorders, Polycystic Ovary Syndrome (PCOS), and infertility in females, among others, which are often required during pregnancy to treat specific disorders. Drug treatment for disorders during pregnancy is generally an option when the potential benefit outweighs known risks. In addition, increasing incidences of gynecological cancers is a key factor expected to significantly drive revenue growth of the market between 2022 and 2030.

According to estimates of American Cancer Society (ACS), over 113,520 individuals were diagnosed with cancers of reproductive organs in the U.S. in 2020. A range of drugs have been listed by National Cancer Institute (NCI), including Cervarix (Recombinant HPV Bivalent Vaccine), Gardasil (Recombinant HPV Quadrivalent Vaccine), and Gardasil 9 (Recombinant HPV Nonavalent Vaccine) for prevention of cervical cancer. Furthermore, several drugs are currently under pipeline for approval, which is expected to rise demand for drugs over the coming years and drive revenue growth of the market.

Obstetrics and Gynecology Drugs Market Drivers

In addition to treatment of cancers of reproductive system, obstetrics and gynecology drugs are also used for treatment of menstrual disorders such as cramps, pre-menstrual syndrome, metrorrhagia, and menorrhagia. Drugs, such as Acetaminophen (Tylenol) or NonSteroidal Anti-Inflammatory Drugs (NSAIDs) including ibuprofen (Advil, Motrin) and naproxen (Aleve), are used for relieving cramp pains. Oral contraceptives are used for regulating menstrual periods and reduce heavy bleeding. According to a 2020 study published in National Center for Biotechnology Information (NCBI), polycystic ovary syndrome has a global prevalence between 4% to 20%. The World Health Organization (WHO) further suggests that over 116 million women are affected by the disorder on a global level. Furthermore, increasing awareness regarding treatment of menstrual disorders is anticipated to rise demand for obstetrics and gynecological drugs, thereby driving revenue growth of the market between 2022 and 2030.

Pharmaceutical companies are increasingly focusing on Research & Development (R&D) activities to produce novel and effective drugs to treat obstetric and gynecological conditions. Institutions, such as National Institute of Child Health and Human Development, have considerably invested in pregnancy clinical trials to gain insights and develop novel ways to assess fetal well-being and placental function. A review article published in July 2022, further explored regulatory requirements for drugs prescribed during pregnancy and safety of need for increasing research activities to validate and verify medication prescribed to gynecological patients.

Obstetrics and Gynecology Drugs Market Restraints

High costs associated with the development and approval of obstetrics and gynecology drugs pose a significant challenge. The research and development process is lengthy, complex, and expensive, with an average cost of bringing a new drug to market estimated at $2.6 billion. These high costs are often passed on to patients and healthcare systems, making access to necessary treatments difficult, especially in developing countries with limited healthcare budgets.

Obstetrics and Gynecology Drugs Market Segment Insights

Obstetrics and Gynecology Drugs Therapeutics Insights:

Based on therapeutics, the obstetrics and gynecology drugs market is segmented into hormonal therapy and non-hormonal therapy.

Dominance of Hormonal Segment:

The hormonal therapy segment is expected to account for largest revenue share during the forecast period. Hormonal therapy held the largest share among therapeutic type in 2021. It is regarded as a systemic treatment as hormone therapy searches and targets for hormones, which circulate throughout the body. Hot flashes and vaginal soreness are two common menopausal symptoms that are most frequently treated with hormone therapy.

In postmenopausal women, hormone therapy has also been shown to minimize fractures and stop bone loss. FDA-approved combined estrogen-progestogen formulations provide adequate dosing of progestogen for endometrial protection and include continuous-cyclic estrogen- progestogen, continuous combined estrogen-progestogen therapy, and intermittent combined estrogen-progestogen therapy. According to a survey, approximately 24% of women aged 40 years or older were current hormone users, out of these, 30% were taking estrogen–progestin therapy and 70% were taking estrogen-only therapy.

Obstetrics and Gynecology Drugs Application Insights:

Based on application, the obstetrics and gynecology drugs market is segmented into contraception, gynecology infections, female infertility, postmenopausal disorders, polycystic ovary syndrome, gynecological cancers, endometriosis, and others.

Dominance of Gynecological Cancers Segment:

The gynecological Cancers segment is expected to register a significantly rapid CAGR growth rate between 2022 and 2030. Hormone therapy has emerged as a spectacular cancer therapeutic option in the recent years. In addition, hormone therapy uses drugs that either lower hormone levels or impede their biological function, to block or limit progression of gynecological malignancies.

Hormone therapy stops growth of cancer cells caused by hormones. As effective treatments for vulvar cancer, cervical cancer, vaginal cancer, uterine cancer, and ovarian cancer, aromatase inhibitors, anti-estrogens, progestin, Estrogen Receptor (ER) antagonists, GnRH agonists, and progestogen are available. Moreover, effectiveness rate of hormone replacement treatment is high. Furthermore, particularly in women with human papillomavirus infection, progestogen and estrogen replacement are linked to a lower incidence of gynecological malignancies and Human Papillomavirus Infection (HPV).

Obstetrics and Gynecology Drugs Distribution Channel Insights:

Based on distribution channel, the obstetrics and gynecology drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Dominance of Hospital Pharmacies Segment:

The hospital pharmacies segment is expected to account for largest revenue share during the forecast period. The hospital pharmacy segment is projected to account a dominant share during the forecast period. Furthermore, increasing prescription of medications at hospitals due to more frequent diagnoses at these institutes is a major factor driving market growth.

Obstetrics and Gynecology Drugs Regional Insights

North America is expected to account for larger revenue share among other regional markets during the forecast period. Increasing number of childbirths and post-partum conditions and rising incidence of polycystic ovary syndrome and other menstrual disorders are major factors rising demand for obstetrics and gynecology drugs in this region and driving revenue growth of the market over the forecast period. According to the U.S. Centers for Disease Control and Prevention (CDC), around 861 women have died due to maternal causes in the U.S. in 2020, compared to 754 in 2019.

The maternal mortality rate was 23.8 in 2020, a considerable increase from 20.1 in 2019. Cases of gynecological cancers have also significantly increased in countries in this region, which is another factor expected to drive demand for obstetrics and gynecology drugs. Statistics of American Cancer Society (ACS) estimate around 19,880 new diagnosis and 12,810 deaths related to ovarian cancer in the U.S. in 2022. ACS figures also suggest around 14,100 new cases and 4,280 deaths related to cervical cancer in 2022. In Canada, Polycystic Ovary Syndrome (PCOS) has been identified among the most common endocrine disorders, with over 1.4 million individuals in the country diagnosed with this disease. Furthermore, robust presence of key pharmaceutical companies and medical centers in countries in this region is expected to drive revenue growth of the market between 2022 and 2030.

Obstetrics and Gynecology Drugs Top Companies and Competitive Landscape

The obstetrics and gynecology drugs market is fairly fragmented, with a number of large and medium-sized market players accounting for majority market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective products.

Some major companies included in the Obstetrics and Gynecology Drugs Market report are:

• Eli Lilly and Company, Ltd.
• Pfizer, Inc.
• Merck & Co., Inc.
• Amgen, Inc.
• Hoffmann-La Roche, Ltd
• AstraZeneca
• Bayer AG
• Abbott
• AbbVie, Inc.
• GlaxoSmithKline plc
• Novartis AG
• Lupin Limited
• Johnson & Johnson
• Ferring B.V.
• TherapeuticsMD, Inc.

Obstetrics and Gynecology Drugs Latest Industry Updates

• In August 2022, Lupin entered into an exclusive licensing agreement with Japanese company I’rom Group Co., Ltd. for conducting clinical trials on biosimilar Denosumab in Japan. Denosumab is indicated for treatment of postmenopausal women with osteoporosis at high risk of fracture and prevention of skeletal-related events in patients with bone metastases from solid tumors among other indications.
• In March 2022, GlaxoSmithKline plc. presented new findings in support of advancing treatment for certain gynecologic cancers, including data evaluating Zejula (niraparib) and Jemperli (dostarlimab) at the upcoming Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.
• In February 2022, Merck KGaA announced in a European work-sharing procedure an extension to the approval for metformin products in EU - Glucophage (metformin hydrochloride [HCL] immediate release), Glucophage XR (metformin HCL extended release) and Stagid (metformin embonate immediate release) - for use throughout pregnancy.

• In February 2021,Ferring Pharmaceuticals, Rebiotix Inc., a Ferring Company, and MyBiotics Pharma Ltd. announced a multi-year strategic collaboration to develop live microbiota-based bio therapeutics to address bacterial vaginosis, a common vaginal infection among women of reproductive age linked to increased risk of miscarriage and complications for pregnancy and fertility.

Obstetrics and Gynecology Drugs Report Summary

Obstetrics and Gynecology Drugs Market Segmentation Analysis

For the purpose of this report, Emergen Research has segmented the global obstetrics and gynecology drugs market based on therapeutics, application, distribution channel, and region:

• Therapeutics Outlook (Revenue, USD Million; 2019–2030)

  • Hormonal Therapy
    1. Estrogen Therapy
    2. Progestin Therapy
    3. Combination Therapy
    4. Thyroid Replacement Therapy
    5. Parathyroid Hormone Therapy
    6. Others
  • Non-hormonal Therapy
    1. Anti-Infective Agents
    2. Anti-Neoplastic Agents
    3. Anti-Inflammatory Agents
    4. Others

• Application Outlook (Revenue, USD Million; 2019–2030)

  • Contraception
  • Gynecology Infections
  • Female Infertility
  • Postmenopausal Disorders
  • Polycystic Ovary Syndrome
  • Gynecological Cancers
  • Endometriosis
  • Others

• Distribution Channel Outlook (Revenue, USD Million; 2019–2030)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

• Regional Outlook (Revenue, USD Million; 2019–2030)

  • North America
    1. U.S.
    2. Canada
  • Europe
    1. Germany
    2. France
    3. UK
    4. Italy
    5. Spain
    6. Rest of Europe
  • Asia Pacific
    1. China
    2. India
    3. Japan
    4. South Korea
    5. Australia
    6. Rest of APAC
  • Latin America
    1. Brazil
    2. Mexico
    3. Rest of LATAM
  • Middle East & Africa
    1. Saudi Arabia
    2. UAE
    3. Africa
    4. Rest of Middle East & Africa